Skip to main content
Premium Trial:

Request an Annual Quote

Scipher Medicine, Roivant Partner on Rheumatology Drug Discovery

NEW YORK – Scipher Medicine said Tuesday that it has formed a strategic partnership with global pharmaceutical company Roivant to advance rheumatology drug discovery and development by integrating Scipher's real-world clinical and genomic data into Roivant's R&D efforts.

Scipher's PrismRA test uses RNA sequencing to gauge the expression of 19 genomic markers to identify patients who are unlikely to respond to specific rheumatoid arthritis therapies and to enable personalized treatment decisions. Roivant will integrate data derived from the development and commercialization of PrismRA to inform its drug development pipeline.

"The combination of genetic data with longitudinal patient records offers a powerful opportunity to uncover deeper insights into disease progression and treatment response, enabling more precise and informed decision-making," Brett Venker, head of real-world evidence at Roivant, said in a statement. "Integrating Scipher's rich dataset will empower us to generate critical insights, accelerate our decision-making process, and advance the development of potentially transformative therapies for patients."

Financial terms of the agreement were not disclosed.

Earlier this month, Waltham, Massachusetts-based Scipher forged a partnership with electronic health record company Omny Health aimed at advancing precision medicine in immunology.